Anticipating Pixantrone Approval, Cell Therapeutics Adopts A "Poison Pill" Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
The shareholder rights plan includes a provision that is intended to forestall a hostile takeover bid.
You may also be interested in...
Cell Therapeutics' Pixantrone Advisory Committee May Include Updated Results Of Pivotal Trial
FDA declined to give the NME for recurring, aggressive non-Hodgkin's lymphoma priority review, but the firm hopes that progression free survival data and safety argument will be compelling to ODAC.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.